MAPT and Alzheimer disease: However, during the last decade, no clinical trials with Aβ-targeted drugs have been successful [5], suggesting that treatment for subsequent events of AD, such as oxidative stress, neuroinflammation, and tau hyperphosphorylation may be equally important.